版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1DepartmentofPharmacologySchoolofPharmacyPharmacology
WhatisPharmacology?
Chapter1
Introductionbasicmedicine
Pharmacologypharmacymedicine
clinicmedicine2--drugbroadlydefinedasanychemicalthataffectlivingprocesses
--usefulinprevention,diagnosis,
treatmentofdiseases
Chapter1
IntroductionWhatisadrug?3SourcesofDrugsAnimalsPlants
MineralsSyntheticsMicrobesGeneticengineeringdrugs4基因工程药物过程示意图①从细胞中分离出DNA①②③④⑤⑥②限制酶截取DNA片断③分离大肠杆菌中的质粒④DNA重组⑤用重组质粒转化大肠杆菌⑥培养大肠杆菌克隆大量基因
drugTaskofPharmacologymedicinepharamacodynamicspharmacokineticsbody6DevelopmentofPharmacology上古时代公元前1世纪明代(公元1596年)近代药理学的发展迄今7Pharmacological
researchofnewdrugs
pharmacodynamics
generalpharmacology
pharmacokinetics
toxicitology1、preclinicaltestsafetypharmacology8Pharmacological
researchofnewdrugs
Ⅰperiod:20~30caseⅡperiod:200~300case
Ⅲperiod:>400case
Ⅳperiod:clinicaltrial→2000case2、
clinicalpharmacologicaltrial9
Section1
BasicactionofdrugsChapter2
Pharmacodynamicsstimulatorsorexcitantsinhibitorsordepressantsstimulationorexcitation
depressionorinhibitiondrugaction
drugeffect
10
localaction
generalaction
Chapter2
Pharmacodynamicstherapeuticeffectadversdrugreactionselectivity
dualism11Chapter2
Pharmacodynamics
Therapeuticeffect
etiologicaltreatment
symptomatictreatment
12Chapter2
PharmacodynamicsAdversdrugreactionsideaction
econdaryreactiontoxicreactionacutetoxcitychronictoxcitycarcinogenesisteratogenesismutagenesisallergicreactionresidualeffect
withdrawalreaction13
Section2
ReceptivetheoryChapter2
PharmacodynamicsLigand(L)Effect(E)Receptor(R)14Chapter2
Pharmacodynamicsreceptortypechannel-linkdreceptorsG-proteincoupledreceptorstyrosinekinase-linkedreceptorsregulategenetranscriptionreceptors15激动药结合区域膜外膜内激动药结合区域
Ligand-gatedionchannelreceptors16G蛋白偶联CN激动药结合区域膜外膜内
G-proteincoupledrecptors17激动药结合区域膜外膜内催化结构区域
Tyrosine-proteinkinasereceptor18激动药结合区域膜外膜内DNA结合区域转录激活区域载体+药物载体-药物复合物载体
+药物载体
Intracellularreceptors19Chapter2
Pharmacodynamicsreceptorregulationdownregulationupregulationhomospecificregulationheterospecificregulation20Chapter2
PharmacodynamicsLRintrinsicactivityaffinityE21Chapter2
Pharmacodynamicsreceptoragonistfullagonistpartialagonistreceptorantagonist
fullantagonistpartialantagonist2223competitiveantagonist24non-competitiveantagonist25non-competitiveantagonist26drugactionandsignaitransduction27Chapter2
PharmacodynamicsgradedresponsequantalresponseDose-responserelationship28Chapter2
Pharmacodynamicsminimumeffectivedose(thresholddose)maximumeffect(Emax)maximaldose(Max-D)medianeffectivedose(ED50)minimumtoxicdose(Tmin)medianlethaldose(LD50)Dose-responserelationshipefficacypotency29Dose-responserelationshipEmaxED50efficacypotency100%50%thresholddoseMax-DTmin30DoseResponseCurveEmaxEmax31Chapter2
PharmacodynamicsLD50therapeuticindex(TI)
=─────ED50LD5safetyindex(SI)=─────ED95(LD1-ED99)safetymargin(SM)=──────×100%ED99safetyevaluationofdrugs3233Chapter3
Pharmacokinetics
absorptiondistributionmetabolism(biotransformation)excretionSection1
physiologicaldispositionofdrugs34PharmacokineticPhaseelimination35Absorptiondistributionexcretiondrugtransportthroughmembranesmetabolismbiotransformation36
Cellmembrane
1)GIepithelialcells2)vascularendothelium3)bloodbrainbarrier(BBB)
4)subcellularmembranes一、Drugtransportacrossmembranes371234GIepithelialcellsVascularendotheliumBloodbrainbarrier(BBB)Subcellularmembranes38A.
simplediffusion1.
PassivetransportB.
facilitated
diffusionC.
aqueousdiffusion39acrossmembraneoflipidacrossaqueouschannelcarriertransportoutsideinside1.
Passivetransport40
simplediffusion
R=D’A(C1-C2)/XR:
diffusionrate
D’:
diffusion
constantA:
areaofmembrane(C1-C2):
concentrationgradientofdrugsX:
thicknessofmembrane41
Foraweakacid
kaHAH++A-[H+][A-]ka=─────[HA]
ka:dissociationconstantpH=-logconcentration[H+]
-logKaispKa42
Foraweakacid
[A-]pKa=pH-log────
[HA]
[A-]pH-pKa
=
log────
[HA]10pH-pKa=
[A-]/[HA]43Foraweakbase
ka[H+][B]BH+H++BKa=─────
[BH+]
[BH+]pKa–pH=log────[B]10pka–pH=
[BH+]
/
[B]44
Foraweakacid
[unionized]pKa=pH+log───────[ionized]
10PH-pka=[ionized]/[unionized]Foraweakbase
[ionized]pKa=pH+log───────[unionized]
10pka-pH=[ionized]/[unionized]45
If[A-]=[HA]or[B]=[BH+]---pKa=pH
---asubstanceishalfionizedandhalfnonionized
MustbecarefulyoumustknowpKa
[A-]pH-pKa=log───[HA]
[BH+]orpKa–pH=log────[B]46
2.activetransportExamle:Na+-K+ATPase47
3.cytosispinocytosisexocytosis4849
1.Absorption
themovementofadrugfromitssiteofadministrationintothebloodstream二、drugprocessinbodyBloodstreamdrugdrug501)
First-passeffectinfluencingfactorthefirstpasseffectcanbeavoidedby…
sublingualrectuminhalationimsc51GIhepaticportalvein
livervenacava
52
2)Bioavailability
fractionofanadministereddrugthatreachesthesystemiccirculationforIV,Bioavailability=1.0
5354Minimumeffectiveconcentration55
2.DistributionBloodstreamdrugdrugenterstheextracellularfluidsandtissuesofthebodydrugcell56
1)
bindingofdrugbyplasmaproteinsinfluencingfactor2)
bloodstreamoforgan3)
affinityoftissue4)
bloodbrainbarrier5)
placentalbarrier5758ApparentVolumeofDistribution(Vd)Vdishypotheticalvolume
Vd=A/C59
3.Metabolism
twophasesoxidationsreductionshydrolyses
thefirstphase
conjugationsthesecondphase60Hepaticmicrosomalenzymesenzymeinhibitorenzymeinducermixedfunctionoxidases61624.Excretion
excretionofkidneysexcretionofbileexcretionofmammarygland63
Hepatoenteralcirculationliver--bilegallbladder
duodenumexcrete4.Excretion
64消除transportandtransformationofdrugs65
Section2
Basicconcept
ofpharmacokineticsA.
Time-concentrationcurvethresholddoseCmaxTpeakTCmin66
B.HalfLife(t1/2)
firstorderkinetics
t1/2=0.693/Kzeroorderkinetics
t1/2=0.5C/K67C.Drugeliminationrate
dc/dt=-KCn
C:concentrationofthedrugK:eliminationrateconstantn=1firstorderkinetics
-dc/dt=KC1n=0zeroorderkinetics
-dc/dt=KC0=Vmax68
D.
Clearance(CL)CL=Vd.Kor0.693.Vd/t1/2690210123456SteadystateconCss.maxCss.min7
E.Steadystateconcentration(Css)
70血药浓度100200300802460002468100200300时间(半衰期)10020030002460ABC8MTCMEC三种不同给药方案对稳态浓度的影响A.缩短给药时间B.增加给药剂量C.负荷量给药71RoutesofDrugAdministrationcommonabbreviations…po
=peros=oraliv
=intravenous=intotheveinim
=intramuscular=intothemusclesc
=subcutaneous=betweentheskinandmuscleip
=intraperitoneal=withintheperitonealcavityicv
=intracerebroventricular= directlyintotheventricleofthebrain72Chapter4
Factorsaffectingeffectofdrugs
ageandsexmentalandpathologicfactorsindividualvariationandgeneticsspeciesvariationSection1
Factorsaboutorganismaspect73ageandsexage
infants
agedpeople74ageandsexsexmalefemale75mentalfactor
spiritandbodydiseasebodyandspiritdiseaseplaceboactions
mentalandpathologicfactors76
mentalandpathologicfactorspathologicfactordystrophyrenalinadequacyhepaticinadequacy77individualvariationandgeneticfactorsindividualvariationhypersensitivereactiont
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 工业机器人操作岗位培训教程
- 银行贷款风险控制策略
- 手术室安全管理与意外评估表模板
- 物业用房租赁合同规范范本汇编
- 三年级日期时间知识点复习资料
- 高三数学几何专题训练方案
- 2025~2026学年重庆市两江中学校八年级上学期期中地理试卷
- 舆情监控与企业危机应对操作方案
- 健康教育复习资料汇编
- 2025-2030中国高铁联锁设备行业市场分析及发展趋势与投资评估研究报告
- 《毛泽东思想概论》与《中国特色社会主义理论体系概论》核心知识点梳理及100个自测题(含答案)
- 成人术后疼痛管理临床实践指南(2025版)
- 论语子张篇课件
- 扶梯咬人应急预案(3篇)
- 2025秋人教版(新教材)初中信息科技七年级(全一册)第一学期知识点及期末测试卷及答案
- 2025 医学急危重症重症重症剥脱性皮炎护理课件
- 医风医德培训课件
- 党的二十届四中全会精神题库
- 锅炉车间输煤机组PLC控制系统设计
- 2025年检验检测机构内部质量控制标准模拟考试试题试卷
- 锅炉房施工进度管理表模板
评论
0/150
提交评论